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Explanatory overview
High-grade serous tubo-ovarian carcinoma (HGSOC) is the most common
tubal/ovarian malignant tumour and is usually diagnosed at an advanced stage.
Historically, primary debulking surgery followed by adjuvant platinum-based
chemotherapy was the recommended management of these patients. However,
since two randomised controlled phase III trials (1, 2) both demonstrated non-inferior
survival after neoadjuvant chemotherapy (NACT) and interval debulking surgery
(IDS) compared to primary debulking surgery, there has been an increasing trend to
treat HGSOC patients with NACT. (3, 4)

Evidence supporting the change in practice is mounting, with the findings of a recent
meta-analysis of 1,607 women showing that NACT is associated with superior rates
of optimal surgical cytoreduction, lower peri-operative mortality as well as postsurgical mortality, and better quality of life compared to primary surgery in patients
with advance ovarian cancer. (5) A cross-sectional analysis that included more than
6000 women treated for advanced epithelial ovarian cancer in the United States,
reported that adoption of NACT resulted in a sizable reduction in mortality within
three years of diagnosis. (3)

Opinion, however, remains divided with calls for better methods of patient selection
and improved efficacy of NACT. (6, 7) While histopathological scoring of tissue
removed at IDS has been routinely used to measure the response to antineoplastic
treatment for many solid tumours such as breast, (8-10) rectum (11, 12) and
oesophagus, (13, 14) until recently, there has been no accepted system for HGSOC
due to studies having small sample size, based on a single site, utilising differing
classification systems and lacking in validation or reproducibility. (15-18)
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Following a publication by Böhm at al., (15) who developed, tested and validated a
three-tier ‘Chemotherapy Response Score’ (CRS) that was reported to be
reproducible and easy for pathologists to use, the International Collaboration on
Cancer Reporting (ICCR) recently recommended the adoption of this grading
system, whilst calling for further studies to confirm its relevance. (19)

In response to the above, the purpose of this thesis was to test the hypothesis that
the CRS score was independently associated with the survival outcomes of patients
with advanced high-grade serous ovarian cancer undergoing NACT-IDS.

Study objectives
Testing the hypothesis that the CRS score is associated with the survival outcomes
of patients with advanced ovarian cancer undergoing NACT-IDS” was assessed in
two stages, each with their own objective:

First objective


To externally validate the CRS scoring system as developed by Bohm et al.
(15) and recommended by the ICCR for HGSOC patients.

Second objective


To determine the prognostic significance of CRS with respect to progression
free survival (PFS) and overall survival (OS) in patients with advanced
HGSOC.
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Thesis overview
This thesis provides a summary of the work undertaken to address the research
objectives. It is divided into three chapters and is supported by a peer-reviewed
publication (the candidate was first author on the publication).

Chapter 1:

Literature review

Provides a literature review and a description of the anatomical location of the ovary,
pathogenesis and aetiology of ovarian cancer, ovarian cancer staging and treatment
regimens, and the significance of the chemotherapy response score.

Chapter 2:

The chemotherapy response score for high-grade serous
ovarian cancer patients treated with NACT and IDS

Addresses objectives one and two by exploring the clinical validity of the
chemotherapy response score, the finding of which resulted in a publication and an
oral presentation at an international conference.

Chapter 3:

Discussion

Presents the final discussion and explores the overall strengths and limitations of
work reported in this thesis and points to directions for future work in this area.
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Chapter 1:
Literature review

13

1.1 Introduction
Ovarian cancer is the seventh most common cancer for incidence and mortality
among women worldwide, accounting for an estimated 239,000 new cases and
152,000 deaths annually. (20)

While age-standardised incidence rates have

varied across the globe, higher rates have been observed in western countries
than those seen in Asia and Africa. However, rates in higher-incidence countries
have generally fallen while those from the lower-incidence countries have risen in
recent decades, meaning the difference between countries is less marked than it
was 30 years ago. (21) In Australia, ovarian cancer is the leading cause of
gynaecologic cancer-related deaths (approximately 5% of all cancer deaths in
women). In 2018, an estimated 1,613 Australian women will be diagnosed with
ovarian cancer with 1,069 dying of the disease. (22)

For the few cases diagnosed early with localised tumour (Stage 1), the 5-year
survival rate is 92% although the disease typically presents at a later stage,
where the 5-year relative survival rate is less than 50%. Overall the 5-year
relative survival rate generally ranges between 30% and 40% but has seen only
very modest increases (2%–4%) since 1995. (23)

Family history is one of the most significant risk factors for ovarian cancer (24)
with first-degree relatives of probands having a 3- to 7-fold increased risk,
especially if multiple relatives are affected, and at an early age of onset. (25)
More recent work has shown that 15-17% of patients diagnosed with HGSOC
carry germline mutations in the BRCA1 and BRCA2 genes. (26)

Multiple other risk factors have been identified through epidemiological research
within implicate hormonal and reproductive factors, such as age at menarche,
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age at menopause, parity, lactation, (25, 27) oral contraceptive use, diabetes
mellitus, body size, life style factors such as diet, alcohol consumption and
physical activity (21) and benign gynaecologic conditions. (28, 29)

Women continue to experience non-specific symptoms such as back pain,
fatigue, persistent abdominal pain, bloating or decreased appetite meaning that
in the majority of cases affected women will present with disease at an advanced
stage (30) (International Federation of Gynaecology and Obstetrics [FIGO] stage
III and IV; see Table 1). (31) As a consequence, until researchers identify
biomarkers that may enable early detection of HGSOC, this disease will continue
to have a poor prognosis with limited treatment options.

1.2 Anatomy of the ovary and fallopian tubes
The ovaries are situated in the pelvis in close proximity to both the pelvic and
abdominal organs (Figure 1). The ovary is the primary endocrine gland of the
female reproductive system (32) and has two main functions (32):


Oocyte production; and



To secrete female sex hormones, oestrogen, progesterone, androgens
and inhibin.
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Figure 1. The female reproductive system. (32)

From: The Editors of Encyclopedia Britannica. Encyclopedia Britannica. Uterus Anatomy [Internet].
Encyclopedia Britannica. 2018 [cited 18 June 2018]. Available from https://www.britannica.com/science/uterus.

1.3 Pathogenesis and aetiology of ovarian cancer
The majority of benign and malignant ovarian tumours will originate from one of
three cell types: epithelial cells, stromal cells or germ cells. (25) In developed
countries, more than 90% of malignant ovarian tumours are epithelial in origin.
(33).

Epithelial ovarian cancer is a heterogeneous disease with histologic

subtypes that differ in their cellular origin, pathogenesis, molecular alterations,
gene expression, and prognosis. (21, 25, 34) Malignant epithelial ovarian cancer,
the most common type of ovarian cancer, is comprised of five main histological
types: high-grade serous (HGSOC; 70%), endometrioid (10%), clear cell (10%),
mucinous (3%) and low-grade serous (<5%). (35, 36)
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The cellular origin and pathogenesis of HGSOC is also not well understood but
appears to comprise other gynaecological tissue. Morphological and genetic
studies have given rise to several hypotheses of aetiology, particularly for
HGSOC that suggest it originates from fallopian tube epithelium. (37-39)

There are a number of theories on how precursor cells in the ovary may over time
become malignant. (27) Historically until around the year 2000, the most
commonly accepted hypothesis was that regular ovulation, also termed
“incessant ovulation”, with the associated disruption and subsequent repair of
ovarian epithelium lead to acquisition of genetic damage in ovarian epithelial cells
and subsequent development of ovarian cancer in susceptible individuals over
time. (29) This explains why pregnancy, breast-feeding and prolonged use of the
combined oral contraceptive pill can decrease a women’s lifetime risk of ovarian
cancer through their inhibitory impact on ovulation. (40)
Alternative hypotheses to this include:


The gonadotropin hypothesis: circulating gonadotropins stimulate the
ovarian epithelium and promote neoplastic transformation. (41)



The hormonal hypothesis: reproductive hormones act directly on the
ovarian epithelium to promote (oestrogens and androgens) or protect
(progestin’s) against cancer. (42)



The inflammation hypothesis: inflammatory mediators from ovulation or
co-existing disease processes damage the epithelium in the ovary and
fallopian tube. (43)
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In their theory on the pathogenesis of ovarian cancer Kurman and Shih proposed
dividing ovarian cancers into two main groups. (44) The first of these groups, type
I tumours tend to be low grade and indolent and frequently confined to the ovary
at presentation.

Their cell origin is from the mullerian system (cervix,

endometrium and uterus) and they include low grade serous, low- grade
endometrioid, clear cell, mucinous and transitional carcinomas. (45) This group
shares similar cell lineage to benign cystic neoplasms and borderline tumours
and importantly lacks the p53 mutation. (45) The second group of tumours, type
II, account for around 75% of tumours including HGSOC, undifferentiated
carcinoma and malignant mixed mesodermal tumours. Importantly p53 mutations
are found in in more than 80% of cancers in keeping with their poor prognosis
and diagnosis at advanced stage. (45)

In the early 2000s a further shift away from the “de novo” ovarian cancer theory
came via the discovery of the serous tubal intraepithelial carcinomas (STIC)
precursor lesions and that ovarian cancer itself involved the ovary as a site
secondarily, with the primary lesion arising elsewhere in the pelvis. (39) The
evidence around the STIC precursor theory largely involved studies of women
with BRCA mutation who had had risk reduction salpingectomy and had their
fallopian tubes examined in great detail. (46) Examining of the fallopian tubes in
this group of women found approximately 5% harbour an early-stage
intramucosal invasive tubal carcinomas, which was designated a serous tubal
intraepithelial carcinomas (STIC) lesion. (46)

STIC is now identified as a precursor lesion for HGSOC, similar to the cervical
intraepithelial neoplasia (CIN) precursors to cervical cancer. (37-39) It is though
that following the development of STIC, there is a latent time window of
18

approximately 5 years prior to the onset of full-blown metastatic HGSC. (39)
Pre-malignant cells from a STIC may shed and implant on the ovarian surface
during ovulation when the fimbriated end of the fallopian tube is in close contact
with the ovary. (39) Additionally, epithelial serous pre cursor’s (ESP) may shed
from the fimbria by a process that is termed “pre cursor escape” and undergo
malignant transformation prior to implanting on the ovary. (39) Importantly, ESPS
have also been shown to contain p53 gene mutations seen in both STIC
precursors and HGSOC. (39, 45)

HGSOC itself is not a single disease and has been classified into molecular
subtypes on the basis of genetic changes (Figure 2). (47) A study by Tothill et
al. of 285 endometroid and HGSOC cancers found a large element of
heterogeneity between the different molecular subtypes of the tumours. In one of
the largest study to date they performed molecular profiling on almost 300
tumours. They showed six main molecular subtypes named C1-C6. Importantly,
cases of HGSOC were largely confined to 4 molecular subtypes. (47) Low grade
and less aggressive tumours were confined to one subtype and those who had
an earlier progression of disease were again more likely to show the reactive
stroma ‘C1’ subtype. (47) There also appears to be a survival advantage for
tumours with a high expression of immune response related genes C4. (48)
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Figure 2. Molecular aberrations identified in HGSOC. (48)

From: Hollis R. L and Gourley C. Genetic and molecular changes in ovarian cancer. Cancer Biol Med. 2016
Jun;13(2):236-47

Both the recent developments in understanding the early aetiology of ovarian
cancer (39, 45) and better understanding and defining heterogeneity within the
HGSOC molecular subtypes, has the potential of redefining screening modalities
for ovarian cancer and also the current recommendation of risk reduction
salpingectomy and oophorectomy tumours in BRCA positive women (39, 45, 47,
48).

The earlier diagnosis of tumour molecular subtypes may also result in

chemotherapy agents being able to be targeted more effectively (see Chapter 3).
(48)

1.4 Diagnosis and staging of ovarian cancer
Initial investigations for a patient with symptoms suspicious for ovarian cancer
include a pelvic ultrasound scan and measurement of the serum cancer antigen25 (CA-125) (49) to determine a Risk of Malignancy Index (RMI). The RMI
combines the results of ultrasound examination, menopausal status and serum
20

levels of cancer antigen 125 (CA-125) to provide a quantitative assessment of the
risk of malignancy. A score of over 200 is predictive (sensitivity 85% and
specificity 97%) for a pre-operative diagnosis of ovarian cancer. (49)
Patients with diffuse disease and abdominal ascites may have fluid aspirated for
diagnostic purposes and this also allows for removal of large volume ascites and
palliation of symptoms. An image guided tissue biopsy, most commonly from an
omental deposit can also allow for rapid histological diagnosis in conjunction with
immunohistochemical analysis to assess both the subtype and grade of the
tumour. (50, 51)
Histopathology and cytology coupled with clinical and imaging features allow a
confident diagnosis of the primary tumour site and provide information needed to
plan treatment. As part of pre-operative planning a CT of the chest, abdomen and
pelvis is frequently performed to facilitate multidisciplinary discussion and
treatment planning. Staging of the tumour is not finalised until surgery is
completed and specimens have been reviewed by anatomical pathologists and
discussed at a meeting of the gynaecological oncology multi-disciplinary team
(MDT), which is the cornerstone of management of patients with gynaecological
cancers. (52) The universally accepted staging of ovarian cancer was first
published in 1973 by the FIGO and revised in 1988 and again in 2014 following
the improvements in knowledge of tumour origins and disease progression. (53)
In countries where appropriately trained personnel and facilities are available,
standard of care for women diagnosed with ovarian cancer includes treatment in
a centralised gynaecologic oncology service with input from gynaecologic
oncologists and pathologists, medical oncologists and radiologists. Management
of patients by a centralised multidisciplinary service has been shown to improve
patient outcomes. (4, 54)
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Table 1. Description and anatomic representation of FIGO staging for ovarian
cancer. (55, 56)

Stage
I
IA

IB

IC

Description
Tumour confined to ovaries or
fallopian tube(s)
Tumour limited to one ovary (capsule
intact) or fallopian tube, no tumour on
ovarian or fallopian tube surface, no
malignant cells in the ascites or
peritoneal washings

Tumour limited to both ovaries
(capsules intact) or fallopian tubes
No tumour on ovarian or fallopian tube
surface
No malignant cells in the ascites or
peritoneal washings
Tumour limited to one or both ovaries
or fallopian tubes, with any of the
following
IC1 surgical spill intra operatively
IC2 capsule ruptures before surgery
or tumour on ovarian or fallopian tube
surface
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II

IC3 malignant cells present in the
ascites or peritoneal washings
Tumour involves one or both ovaries
or fallopian tubes with pelvic
extension (below pelvic brim) or
peritoneal cancer

IIA

Extension and/or implants on the
uterus and/or fallopian tubes/and/or
ovaries

Image

IIB

III

IIIA

IIIA2

IIIB

IIIC

IV

Extension to other intraperitoneal
tissues

Tumour involves one or both ovaries
or fallopian tubes with cytologically or
histologically confirmed spread
outside the pelvis and metastasis to
retroperitoneal lymph nodes

Metastasis to the retroperitoneal
lymph nodes with or without
microscopic peritoneal involvement
beyond the pelvis
IIIA1 positive retroperitoneal LN only
IIIA1i Metastasis </= 10mm in
dimension (tumour not LN dimension)
IIIA1ii Metastasis >10mm in greatest
dimension
Microscopic extrapelvic (above pelvic
Abrim) peritoneal involvement with or
without positive retroperitoneal nodes
Macroscopic peritoneal metastasis
beyond the pelvic brim </= 2cm with
or without positive retroperitoneal
nodes. Includes extension to capsule
of liver/spleen.
Macroscopic peritoneal metastasis
beyond the pelvic brim > 2cm with or
without positive retroperitoneal nodes.
Includes extension to capsule of
liver/spleen.
IVA pleural effusion with positive
cytology
IVB hepatic and/or splenic
parenchymal metastasis or metastasis
to extra abdominal organs (including
inguinal lymph nodes and lymph
nodes outside of the abdominal
cavity)
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1.5 Treatment options for advanced high-grade serous ovarian
cancer of the ovary, fallopian tube or peritoneum.
Treatment for HGSOC has consisted of primary debulking surgery and adjuvant
platinum and taxane-based chemotherapy as first line therapy. (4, 30) The single
most important prognostic factor is the volume of residual disease (refer to Table
1) at the conclusion of primary surgery. (30) Patients with residual disease > 1cm
in maximal diameter have worse survival compared to those who are optimally
cytoreduced (< 1 cm) or who have no macroscopic residual disease. (57-59).
1.5.1 Primary debulking surgery (PDS)
There are several aims of PDS, including:


Removal of large necrotic areas within tumour bulk with associated poor
blood supply and concurrent poor proliferative activity, resulting in
improved chemotherapy success. (60)



Overall improvement in patient condition and immune function.



Removing resistant clones present at the start of treatment that may
cause chemotherapy failure and earlier recurrence of disease. (61, 62)

The current approach to surgery includes a hysterectomy, bilateral salpingooophorectomy, tumour debulking (which may involve bowel resection +/lymphadenectomy) and omentectomy so that a woman is ideally debulked to nil
macroscopic residual disease, also termed R=0. (63-66) Cytoreductive surgery is
considered ‘optimal’ if the largest residual tumour after surgery is < 1cm (64). If
possible, debulking to nil macroscopic residual is the goal of surgery.
Internationally, surgeons report on debulking success and the sites of residual
disease left at the conclusion of surgery, using the following international criteria.
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Table 2. Classification of residual disease at debulking surgery for ovarian
cancer. (58, 67)
Residual disease (cm)
0

Description
Debulked to nil macroscopic disease

1

The largest amount of residual disease is < 10 mm

>1

The amount of measurable residual disease is
between 10-20 mm

>2

Bulky disease is left

Griffiths et al., (68) in 1975, were the first to report on the survival benefits in
patients who were cytoreduced in surgery to less than 1.5 cm of residual disease.
Since this publication, there have been many subsequent series and Cochrane
meta-analyses that demonstrated improved survival benefits following optimal
debulking and debulking to no residual disease. (69) This is demonstrated
visually in the Kaplan Meier curve from Chi et al.’s meta-analysis of PDS for
patients with bulky disease, published in 2012 (Figure 2). (6) Other factors that
improve a women’s overall survival in advanced ovarian cancer include (FIGO)
stage at time of diagnosis, involvement of a gynaecological oncologist performing
surgery, age <75, performance status and comorbidities at time of treatment. (1,
64, 66)
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Figure 3. Progression-free survival by residual disease status in patients
undergoing primary debulking surgery for advanced ovarian cancer. (6)

From: Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky
advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during
an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Gynecologic Oncology. 2012;124(1):10-4.

Understandably, upfront optimal debulking to nil macroscopic disease translates
into long arduous surgery and is associated with increased perioperative
morbidity and mortality. The subset of women presenting with advanced stage
disease who are not considered suitable candidates for PDS due to frailty and coexisting medical comorbidities, may benefit from NACT (refer to section 1.5.3).
1.5.2

The role of adjuvant chemotherapy in advanced ovarian cancer: Six
cycles of carboplatin and paclitaxel - where have we come from and how
did we get here?

Following optimal debulking surgery, women receive six cycles of adjuvant
chemotherapy completing treatment. (70-73) For the purpose of this thesis, the
key landmark trials that have shaped current chemotherapy practice in the
treatment of advanced ovarian cancer (stage III and IV only) will be discussed.
Ovarian cancer has been treated with platinum-based agents (i.e. cisplatin) since
the late 1970’s and carboplatin-based combinations have been the standard of
26

care for over 15 years. (74-77) Cisplatin significantly improved the overall survival
(OS) for ovarian cancer patients, leading to its adoption as the cornerstone of
most chemotherapy regimens. (74-77) Since the mid-1980’s, carboplatin (a
cisplatin analogue) has been administered as it has a superior toxicity profile
compared to cisplatin. (74-77). The next major milestone in epithelial ovarian
cancer treatment was the introduction of the taxane compound paclitaxel, which
in combination with cisplatin was shown to be superior to cisplatin and
cyclophosphamide (GOG 111). (72, 73) Despite other drug combinations being
investigated (such as in the ICON 3 trial (78), carboplatin and paclitaxel remains
the ‘backbone’ for the treatment of advanced ovarian cancer.
Treatment can be curative (for patients with early stage disease); however, most
women with HGSOC will develop recurrent disease with progressively shorter
disease-free

intervals,

and

these

episodes

ultimately

culminate

in

chemoresistance. (78) The disease may be managed for more than five years for
patients who had a complete pathological response after surgery and whose
disease continues to respond to platinum-based drugs. (74, 79, 80)
Resistance to chemotherapy may result from a number of mechanisms including
altered membrane transport, alterations in target enzymes, decreased drug
activation, increased drug metabolism and inactivation, subcellular redistribution,
enhanced deoxyribonucleic acid (DNA) repair, and failure of apoptosis due to
mutated cell cycle proteins. (81, 82) It is unlikely that chemotherapy resistance
would result from a single mechanism, and it is thought that multiple molecular
mechanisms ultimately prevent the tumour from responding to the chemotherapy.
(81) Even the smallest detectable cancers will eventually contain drug-resistant
clones and the best chance of cure is to use two different non–cross-resistant
chemotherapy regimens in alternating cycles.
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Chemotherapy works by first order kinetics killing a constant fraction of cells
dividing at any one time rather than a constant number of tumour cells. This
means that a single dose of chemotherapy is unlikely to be curative. This ‘log kill’
hypothesis explains the need for intermittent courses of treatment to achieve the
magnitude of cell kill to produce tumour regression. (83-85)
Dose dense weekly paclitaxel has been compared to conventional three-weekly
administration in a Japanese population, which showed improved overall survival
in the dose dense arm from 62 to 100 months. (86) It is important to note that
ethnic differences in the expression of alleles involved in the chemotherapy drug
metabolism have been reported, and when this when this study was replicated in
a Caucasian population the same overall survival benefits were not
demonstrated, and thus, outside of Japan, the dose dense regime is not
recommended. (87)
1.5.3

NACT as an alternative to primary debulking surgery: An emerging
alternative

NACT is defined as the administration of platinum-based chemotherapy prior to
IDS to reduce tumour size and may be considered an alternative to primary
debulking surgery (refer to section 1.8.1) for selected patients with HGSOC.
Primary debulking surgery (PDS) carries a high risk of postoperative
complications; therefore, NACT before cytoreductive surgery of women with
advanced HGSOC was proposed as a means to reduce the surgical complexity
in high-risk women with advanced ovarian cancer. (2)
There are several reasons to consider offering NACT as an alternative to up-front
debulking surgery for HGSOC patients, these include (1):
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If the disease is suspected to be unresectable (unlikely to be successfully
debulked to R0) with primary debulking surgery (i.e. if the tumour involves
the porta hepatis or the small bowel mesentery)



Patients with high perioperative risk (e.g. those who have medical comorbidities with a poor performance status at time of diagnosis).

Treatment of HGSOC with NACT has remained controversial due to the
limitations and variations in existing international research. Several studies have
suggested that NACT may have superior outcomes compared to primary
debulking surgery (including patients with advanced epithelial ovarian cancer)
reporting that NACT was associated with achieving a higher rate of optimal
cytoreduction and lower perioperative morbidity when compared to PDS. (88-90)
However, opposing studies also exist and report that a lower optimal
cytoreduction rate, (91-93) similar residual disease (94) and perioperative
morbidity (95, 96) was present for NACT patients compared to those that had
PDS.
A recent meta-analysis study further fuelled debate by reporting that NACT-IDS
improved perioperative outcomes and optimal cytoreduction rates and was not
inferior to PDS-CT in terms of survival outcomes. (97) The later study concluded
that future research should focus on improving the efficiency of NACT.
In addition to the existing retrospective and observational studies, several
randomised controlled trials (RCTs) (1, 2, 98-100) have investigated NACT and
the associated outcomes for patients with advanced epithelial ovarian cancer.
Two of these RCTs provided gynaecological oncologists worldwide with
compelling evidence to recommend NACT to patients as an alternative noninferior option to primary surgery with equivalent overall survival and less perioperative morbidity and mortality. (1, 101)
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Whilst the evidence from these trials has led to an increasing trend worldwide to
treat patients with NACT, (1, 101) these two trials have also received some
criticism.

Firstly, there was mismatched randomisation between groups and

patients with bulkier disease in the NACT arms. Optimal debulking rates to R0
and R1 were much lower compared to some centres in North America, as was
the resultant progression free survival and overall survival. Residual large tumour
bulk at the start of chemotherapy is known to be associated with the decreased
efficacy of chemotherapy and the earlier development of chemotherapy resistant
clones during the course of NACT, and that may explain the lower survival rates.

Lastly, critics have highlighted the large number of recruiting centres in each trial
with low caseloads. The low rates of R0 achieved called into question the level of
surgical expertise at these centres. Previous authors have expressed concerns
that the results of these two trials may encourage gynaecological surgeons to
adopt a more conservative approach to ovarian cancer surgery and therefore
may lead to deskilling of the surgical workforce. (6, 7) In an effort to address
some of these concerns the TRUST trial (102) has been developed and is
currently recruiting patients.

The ultimate decision on whether a patient undergoes PDS or NACT is after
discussion at a gynaecological oncology MDT (see Figure 3) involving input from
pathologists, radiologists, oncologists and gynaecologic oncology surgeons. The
MDT takes into consideration a patient’s biological age, functional status and
disease distribution based on computed tomography (CT) imaging and also
considers the surgeon’s confidence to achieve nil macroscopic disease from
either upfront primary debulking or following NACT. However, the sensitivity of
CT to predict optimal cytoreduction pre-operatively is low (103) and laparoscopic
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pre-staging has been suggested as an alternative to more accurately predict
outcome of debulking surgery. (18) Lastly there is increasing evidence around
tumour molecular testing and the biology of certain subtypes being more likely to
have upper abdominal disease distribution and increased post operative
morbidity. There may be a role for molecular subtype testing in planning for
primary therapy in advanced HGSOC. (47, 104)
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Figure 4. Current approach to treat high-grade serous ovarian cancer.

1.6 Development of the chemotherapy response score system
The use of NACT and IDS as an alternative to PDS has allowed anatomical
pathologists the opportunity to assess the early tumour response of
chemotherapy agents in interval debulking surgical specimens. This assessment
of tumour response to NACT is both established and routinely reported on in
other solid tumours including breast, (8-10) rectum, (11, 12) oesophagus, (13, 14)
stomach and colon/rectum. (100, 105-107) The tumour response regression in
these organs has been known to provide prognostic information and to guide
post-operative adjuvant treatment planning, (8-10) and research into its
prognostic role in HGSOC is greatly needed.

1.6.1 The history of the CRS in ovarian cancer
The evidence for histological tumour regression following NACT in patients with
advanced ovarian cancer has been limited and conflicting. Several widely used
tumour regression-grading systems have been considered for gynaecological
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cancers; however, the systems used were unnecessarily complex (e.g. breast
cancer tumour regression systems also included assessment of lymph nodes).
Although suggested tumour grading systems for gastrointestinal tumours were
relatively simple to use, the reproducibility of results remains highly variable.
(108) Consequently, further investigation into a classification system specifically
for HGSOC required further development and investigation.
Four observational studies investigated and assessed tumour regression after
NACT in advanced‐stage HGSOC and reported a correlation between the tumour
response and overall survival. (17, 109-111) Unfortunately, all studies used
different tumour regression scoring criteria, did not validate their criteria in
independent

series

and

did

not

evaluate

methodologies. (17, 109-111) (refer to Table 3).
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the

reproducibility

of

their

Table 3. Summary of studies that investigated tumour regression scores in response to neoadjuvant debulking surgery for advanced ovarian
cancer patients.
First author

Year

Sassen S, et al.
(111)

2007

Number of
patients
49

Ovarian cancer
histologic types
Serous and
endometrioid

Predicted
PFS

Predicted
OS

No

Yes

Study limitations





Le T, et al. (17)

2007

62

Muraji M, et al.
(109)

2012

124

Petrillo M, et al.
(18)

2014

322

Serous,
mucinous,
endometroids,
clear cells
anaplastic.
Serous,
mucinous,
endometroids,
clear cells and
‘other’
Serous and
‘others’

PFS – progression free survival, OS – overall survival.
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No

Yes




No

No

Yes

Yes

Small sample sizes
Observer dependence inherent to any
semi quantitative evaluation
Sampling error due to tumour
heterogeneity
Some patients received further palliative
treatment that may have had an impact on
overall survival that was not measured
Retrospective design, which has
unavoidable selection bias
Unavailability of some pathologic slides for
review limiting the power of our analysis



Retrospective design, which has
unavoidable selection bias



Retrospective design, which has
unavoidable selection bias

In 2015, a study by Böhm et al. (15) described a three‐tier scoring system (the
Chemotherapy Response Score [CRS]) that was highly reproducible and easy for
pathologists to apply in their clinical setting, regardless of experience level in
gynaecological oncology pathology (see Table 4). Using a modification of the
Dworak system, (12) the study demonstrated good inter‐observer reproducibility
and a statistically significant association with the clinical outcomes in both the test
cohort (60 patients) and validation cohort (71 patients) with HGSOC stage III or
IV. Furthermore, the study design identified that application of the CRS to the
omental tumour deposit was superior to the application of the CRS to the primary
tumour. A study published by Said et al. in 2017 further examined the CRS
reproducibility. 40 samples were examined amongst 5 different groups each with
three pathologists of varying ability. In this study the CRS system was found to
be highly reproducible among all the pathologists' groups (K=0.761). Most
notably the interobserver reproducibility was K=0.926 in those patients identified
as CRS3. (112)

Table 4. The final three-tier CRS score as adopted by the ICCR in 2015. (15)
Score

Description

CRS 1

No or minimal tumour response. Mainly viable tumour with no or
minimal regression-associated fibro inflammatory changes, limited to
a few foci: cases in which it is difficult to decide between regression
and tumour-associated desmoplasia or inflammatory cell infiltration.

CRS 2

Appreciable tumour response amid viable tumour that is readily
identifiable. Tumour is regularly distributed, ranging from multifocal or
diffuse regression-associated fibro inflammatory changes with viable
tumour in sheets, streaks, or nodules to extensive regressionassociated fibro inflammatory changes with multifocal tumour, which
is easily identifiable.

35

CRS 3

Complete or near-complete response with no residual tumour OR
minimal irregularly scattered tumour foci seen as individual cells, cell
groups, or nodules up to 2 mm maximum size. Mainly regressionassociated fibroinflammatory changes or, in rare cases, no or very
little residual tumour in the complete absence of any inflammatory
response. It is advisable to record whether there is no residual
tumour or whether there is microscopic residual tumour present.

1.7 Summary
With accumulating evidence that NACT-IDS offers similar outcomes to the
traditional pathway of PDS followed by chemotherapy for the subgroup (poor
functional status either related to the disease or co-morbidities) of women with
advanced stage HGSOC, (7) the three-tier CRS developed by Böhm provides an
opportunity to reliably assess a patient’s response to the chemotherapy.
The ICCR recommended that the CRS be incorporated as part of the routine
pathological assessment until further studies assessing the CRS became
available. Therefore, a retrospective analysis of the prognostic role of the CRS in
women with advanced HGSOC undergoing neoadjuvant chemotherapy in
Western Australia would help address this need.
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Chapter 2:
Prognostic role of histologic tumour regression in patients
receiving neoadjuvant chemotherapy for high-grade serous
tubo-ovarian carcinoma1

1

This is the Author’s original manuscript of an article published by Coghlan E, Meniawy TM, Munro A, Bulsara
M, Stewart CJ, Tan A, et al. Prognostic role of histological tumor regression in patients receiving neoadjuvant
chemotherapy for high-grade serous tubo-ovarian carcinoma. International Journal of Gynecological Cancer:
Official Journal of the International Gynecological Cancer Society. 2017;27(4):708-13.
Available online or see p.55 of thesis.
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2.1 Introduction

Ovarian cancer is a highly lethal malignancy accounting for more than 140,000
deaths annually worldwide. Most women with ovarian cancer are diagnosed with
advanced stage disease, for which the standard treatment is a combination of
debulking surgery and platinum-based chemotherapy.2 Since two randomized
phase 3 clinical trials demonstrated equivalent survival and reduced morbidity
after neoadjuvant chemotherapy (NACT) and interval debulking surgery (IDS)
compared with primary surgery,3,4 there has been an increasing trend in many
countries to treat such patients with NACT.

Histopathological tumour response to NACT is routinely assessed in breast,
esophageal, and rectal cancers,5-7 but until recently, there has not been an
accepted scoring system for high-grade serous tubo-ovarian carcinoma
(HGSOC), the most common histological subtype of epithelial tubo-ovarian
cancer. Several studies have attempted to quantify chemo- therapy response in
HGSOC and to correlate this with survival,8-11 but their findings have been
inconsistent, and none has been independently validated. Recently, Bohm et al.12
reported a three-tier chemotherapy response score (CRS) in a test cohort of 62
HGSOC tissue specimens resected at IDS. This predicted progression-free
survival (PFS) and overall survival (OS) in the test group and in a subsequent
validation cohort of 71 patients. Despite calling for further studies to confirm these
findings, the International Collaboration on Cancer Reporting has recently
recommended the use of the CRS for the histological grading of NACT effect in
HGSOC.13

The aim of the current study was to externally validate the prognostic role of this
proposed chemotherapy response scoring system in an equivalent-sized
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independent cohort of patients with advanced HGSOC treated with NACT and
IDS.

2.2 Patients and methods

2.2.1 Study participants

Consecutive patients diagnosed with HGSOC between January 1, 2010, and
December 31, 2014, were identified from the weekly Western Australian
gynecologic oncology tumour board, a multidisciplinary meeting of the Western
Australian Gynecologic Cancer Service, in which almost all patients presenting
with gynecological cancer in the state are reviewed. Patients were eligible if they
had histologically and/or cytologically confirmed stages IIIC and IV ovarian,
fallopian tube, or primary peritoneal high-grade serous carcinoma - hereafter
collectively referred to as HGSOC - treated by NACT and IDS. Because the CRS
system requires a histological assessment of tumour response specifically within
the omentum, patients who were classified as stage IIIC according to earlier (pre2014) FIGO criteria with metastatic disease confined to the lymph nodes were
excluded from the study (see the ‘‘Pathology Review’’ section). Follow-up data
were available up to the study census date, November 23, 2016. Laboratory and
clinical data including patient age, FIGO stage, chemotherapy regimen, the
surgeon’s visual assessment of completeness of the IDS (macroscopic residual
disease classified as zero residual, >1 or <1 cm), and serum CA-125 at baseline
and before IDS were obtained from the patient’s medical records. Germline
BRCA mutation status was ascertained from the state-wide Genetic Services
Western Australia, where available. Neoadjuvant chemotherapy was routinely
administered as an initial combination of intravenous carboplatin (AUC 5Y6) and
paclitaxel (either q3 weekly, 175 mg/m2, or q1 weekly, 80 mg/m2). Interval
debulking surgery was performed by midline laparotomy in all cases and included
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total extrafascial hysterectomy, bilateral salpingo oophorectomy, and infracolic
omentectomy as a minimum.

Study data were obtained after ethical approval from the St John of God Subiaco
Hospital Human Research Ethics Committee (reference no. 806) and The
University of Notre Dame Australia (Fremantle) Human Research Ethics
Committee (reference no. 016106F).

2.2.2 Pathology review

Slides obtained from formalin-fixed paraffin-embedded tissue blocks were
reviewed by one of three gynecological pathologists (A.T., C.J.R.S., M.H.E.K.),
who assigned a CRS independently to any given in the original histopathology
reports. Tumour regression scores were then assigned based on the omental
sample showing the least NACT response according to the proposed CRS, as
summarized as follows. In general, a CRS of 1 and a CRS of 3 equated to
13

greater than 95% and less than 5% tumour viability, respectively :


Chemotherapy response score of 1. No or minimal tumour response.
Mainly viable tumour with no or minimal tumour regression - associated
fibroinflammatory changes, limited to a few foci: cases in which it is
difficult

to

decide

between

regression

and

tumour-associated

desmoplasia or inflammatory cell infiltration.


Chemotherapy response score of 2. Appreciable tumour response amid
viable tumour that is readily identifiable. Tumour is regularly distributed,
ranging from multifocal or diffuse regression-associated fibroinflammatory
changes with viable tumour in sheets, streaks, or nodules to extensive
regression-associated fibroinflammatory changes with easily identifiable
multifocal residual tumour.
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Chemotherapy response score of 3. Complete or near complete
response with no residual tumour or minimal irregularly scattered tumour
foci seen as individual cells, cell groups, or nodules of up to 2-mm
maximum size. Mainly regression-associated fibroinflammatory changes
or, in rare cases, no or very little residual tumour in the complete absence
of any inflammatory response.

Consensus scoring was achieved after review and discussion in a minority of
cases where there was initial difficulty separating a CRS of 1 from a CRS of 2, or
a CRS of 2 from a CRS of 3.

2.3 Statistics

Statistical analysis was performed using the statistical software program Stata
13.0 (Stata Statistical Software Release 13; Stata Corp LP, College Station, TX).
Fisher exact test was used to examine group differences between CRS, PFS,
and OS. Time-to-event analysis was performed using Cox models to investigate
patient and clinical factors associated with PFS and OS in univariate and
multivariate models. Progression-free survival was defined as the time from the
commencement of NACT to disease recurrence or death (whichever was the
earliest) or to the date of the last follow-up for patients who had not recurred
before the study census date. Overall survival was defined as the time from the
commencement of NACT to death. Variables included in the model were age at
diagnosis (years), the stage of disease, the surgeon’s visual assessment of
completeness of the IDS (macroscopic residual disease), and the CRS. Statistical
significance was determined as a P value less than 0.05, and the 95%
confidence intervals (CIs) for hazard rate ratios were calculated. Plausible
interaction terms were tested using likelihood ratio tests. Violation of the Cox
model proportional hazard assumption was tested using Schoenfeld residuals.
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2.4 Results

Of 620 patients diagnosed with tubo-ovarian cancer between January 1, 2010,
and December 31, 2014, 93 patients (15%) were treated by NACT. Patients were
excluded if metastatic disease was confined to the lymph nodes (n = 2), tumour
histology was not high-grade serous carcinoma (n = 15), or there was no omental
disease (n = 5). Seventy-one patients were eligible for analysis. Fifty-one patients
(71.8%) had radiological stage IIIC disease, and 20 (28.2%) had stage IV
disease. Of the 71 patients, 45 (63.5%) completed 3 cycles of NACT before
interval surgery. Eleven patients (15.5%) received 4 cycles, 10 (14%) had more
than 4 cycles, and 5 (7%) completed less than 3 cycles before IDS
(Supplementary Table 10). Interval surgery was scheduled approximately 21
days after the last NACT cycle. Of the 71 patients in the study cohort, 19, 29, and
23 patients had CRSs of 1, 2, and 3, respectively. An overview of the study
cohort is presented in Figure 5. Patient characteristics, details of NACT regimen,
and clinicopathological findings are shown in Table 5. Median age at diagnosis
was 67 years (range, 31.3 to 85 years). At the census date of November 23,
2016, 58 (82%) patients had recurred and 32 (45%) had died of any cause (Fig.
4).

Figure 5. Overview of the study cohort.
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The results of the univariate and multivariate analyses for PFS are summarized in
Table 6. Univariate analysis indicated that patients with a CRS of 1 (CRS of 1 vs
CRS of 3; hazard ratio [HR], 3.77; 95% CI, 1.83-7.78; P = 0.000) and any
macroscopic residual disease as visualized by the surgeon at the completion of
interval debulking (any disease vs R0; HR, 1.99; 95% CI, 1.17-3.38; P = 0.011)
were at an increased risk of progression. Patients with a CRS of 1 had a
significantly shorter PFS compared with those with a CRS of 3 (median PFS, 11
vs 26 months). In a multivariate model, the CRS retained significance for PFS
(CRS of 1 vs CRS of 3; HR, 3.13; 95% CI, 1.43-6.87; P = 0.004).

A Kaplan-Meier graph (Fig. 5) was constructed reporting OS by CRS (censoring
women at the time of death or last known follow-up date). More than 50% of the
patients with a CRS of 1 were deceased by 24 months compared with 16% of
patients with a CRS of 3.
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Table 5. Patient baseline characteristics, histologic scoring of tissue and surgical
outcomes at surgical interval debulking.
Characteristic
Median age in years (range)

Study cohort
Percentage
(N=71)
(%)
67 (31.3 – 85)

Neoadjuvant chemotherapy regimen
q1 weekly

53

74.6

q3 weekly

18

25.4

Outcome of interval debulking surgery (residual disease)
Zero residual (R0)
39
26
1cm
> 1 cm
6

54.9
36.6
8.5

CRS Score
CRS 1
CRS 2
CRS 3

19
29
23

26.8
40.8
32.4

Disease distribution*
Lower abdominal
Upper abdominal

27
44

38
62

Total cycles of chemotherapy (neoadjuvant + adjuvant) administered
51
84.5
6
>6
20
15.5
Did chemotherapy regimen change post interval debulking surgery?
No
Yes

60
11

84.5
15.5

< 86
 86

19
49

26.8
69.0

Unknown

3

4.2

Germline BRCA mutation status
BRCA1
BRCA2
Inconclusive
Unknown
Patient declined testing
Did not qualify for testing

4
1
17
45
3
1

5.6
1.4
24.0
63.4
4.2
1.4

CA-125 overall percentage decrease
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Table 6. Univariate and multivariate survival analysis of prognostic factors for progression free survival.

Factors

Univariate analysis
Hazard ratio
95% Confidence
Interval

p

Hazard ratio

Multivariate analysis
95% Confidence Interval

p

CRS
Score 1
Score 2
Score 3

3.77
1.85
1.00

1.83 – 7.78
0.96 – 3.55
-

0.000
0.064
-

3.13
1.71
1.00

1.43 – 6.87
0.88 – 3.36
–

0.004
0.116
-

Age at diagnosis

1.00

0.98 – 1.03

0.874

1.00

0.97 – 1.02

0.619

IIIC
IV

1.00
0.88

0.49 – 1.57

0.657

1.00
0.70

0.37 – 1.34

0.286

Residual disease at IDS
R0

1.00

-

-

1.00

-

-

Any disease present

1.99

1.17 – 3.38

0.011

1.60

0.88 – 2.91

0.120

FIGO stage

CRS; Chemotherapy Response Score; FIGO, International Federation of Gynaecology and Obstetrics; IDS, Interval debulking
surgery.
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Figure 6. Estimation of PFS according to pathological evaluation (CRS 1, 2 or 3)
for patients who received NACT.
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Table 7. Univariate and multivariate survival analysis of prognostic factors for overall survival.

Factors

Univariate analysis
Hazard ratio
95% CI

p

Multivariate analysis
Hazard ratio
95% CI

p

CRS
Score 1
Score 2
Score 3

2.81
1.41
1.00

1.16 – 6.79
0.56 – 3.52
-

0.022
0.462
-

2.39
1.21
1.00

0.47 – 3.08
0.90 – 6.30
-

0.079
0.695
-

Age at diagnosis

1.02

0.98 – 1.06

0.293

1.03

0.98 – 1.08

0.198

IIIC
IV

1.00
1.45

0.71 – 2.96

0.306

1.00
1.89

0.86 – 4.15

0.110

Residual disease at IDS
R0
Any disease present

1.00
1.91

0.94- 3.89

0.073

1.00
1.31

0.60 – 2.89

0.497

FIGO stage

CRS, Chemotherapy Response Score; FIGO, International Federation of Gynecology and Obstetrics; IDS, Interval debulking surgery.
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Figure 7. Estimation of OS according to pathological evaluation (CRS 1, 2 or 3)
for patients who received NACT.
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As per Bohm et al., a multivariate survival analysis of prognostic factors for PFS
combining CRSs of 1 and 2 versus CRS of 3 is shown in Table 8 and the
corresponding Kaplan-Meier graph in Supplementary Figure 5. Patients with
CRSs of 1 and 2 combined were twice as likely to progress during the study
period compared with patients with a CRS of 3 (HR, 2.0; 95% CI, 1.06-3.78; P =
0.032; median PFS, 16 vs 26 months). The CRS was not significant for OS
(CRSs of 1 and 2 vs 3; HR, 1.57; 95% CI, 0.68-3.65; P = 0.291) (Table 10 and
Supplementary Figure 7). The results of the univariate and multivariate analyses
for OS are summarized in Table 7.

Complete CA-125 data were available for 68 patients (95.8%). Median pretreatment levels were 773.5 kU/L (range, 81-34,000 kU/L). Sixty-three patients
(88.7%) had a reduction of 50% or greater, and 41 (60.3%) had a reduction 90%
or greater from baseline to pre-IDS levels. CA-125 reduction did not correlate
with the CRS (P = 0.751) (Table 10). Germline BRCA mutation status was also
investigated, but most of the patients (63.4%) had not undergone testing, and
therefore, this variable was not included in the statistical analysis.

In additional multivariate analyses including the year of entry (categorized as
2009-2012 and 2013-2014), the chemo- therapy regimen (weekly vs threeweekly paclitaxel), and the number of NACT cycles before IDS, there was no
significant association between these variables and PFS or OS (Supplementary
Tables 8-12).

2.5 Discussion

To our knowledge, this is the first external study to validate the CRS described by
Bohm et al., which has been proposed by the International Collaboration on
Cancer Reporting for use in reporting HGSOC after NACT and IDS. 13. In our
study, the CRS (CRSs of 1 and 2 vs CRS of 3) strongly predicted PFS and OS
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on univariate analysis, consistent with the findings of Bohm et al. The CRS
retained prognostic significance for PFS on multivariate analysis when the HRs
were adjusted for age, disease stage, and macroscopic residual disease as
visualized by the surgeon at the completion of interval debulking. On multivariate
analysis, the CRS was not significant for OS and this is also consistent with the
findings of Bohm et al.

Data from previous studies that have investigated the prognostic role of
histological tumour response to NACT in epithelial tubo-ovarian cancer are
conflicting. In a retrospective cohort of 58 patients who were free of macroscopic
residual disease after IDS, tumour response did not reliably predict survival.8 In
contrast, a recent retrospective analysis of 57 epithelial ovarian cancer patients
demonstrated that complete pathological response (defined as no residual
microscopic tumour in the surgical resection specimens) was associated with
PFS but not with OS.14. In another study of 124 patients treated by NACT, lack of
any measurable tumour regression in the histopathology specimens of 11
patients was associated with worse OS. It is difficult to draw meaningful
conclusions from the findings of these studies because of heterogeneity in the
criteria used to classify tumour regression, histological ovarian cancer subtypes
included in their cohorts, and duration of follow-up.

After treatment with NACT, complete resection of all macroscopic disease at
interval surgery has been shown to be the strongest independent variable in
predicting OS in 2 randomized phase 3 clinical trials.3,4 In the present study,
macroscopic residual disease at surgery was significantly associated with worse
PFS on univariate analysis but did not retain significance on multivariate analysis.
There was a nonsignificant trend to worse OS for any macroscopic residual
disease on univariate analysis.

Our study has several limitations including the selection bias inherent in its
retrospective design, small sample size, and the relatively short median follow50

up. Germline and somatic BRCA mutations are associated with improved PFS
and OS,15-18 and it is a limitation of our study that it was not possible to ascertain
mutation status for over 60% of the cohort because mutation testing was not part
of routine care in Western Australia until 2013.

The CRS has been shown to have a high interobserver reproducibility, especially
in identifying the subgroup of patients with the best chemotherapy response,19
but its prognostic relevance based on the current findings is uncertain. The CRS
may be used as an intermediate end point in clinical trials because it can be
measured earlier than disease progression and OS and might also be used to
stratify patients for clinical trials, possibly including changes in chemotherapy for
apparent nonresponders, post-IDS. The role of the CRS in predicting survival in
patients with HGSOC treated by NACT requires prospective validation in an
unselected cohort, ideally as part of a randomized controlled trial of NACT versus
primary debulking surgery, such as the EORTC 55971 TRUST trial, which has
recently started recruiting.20 The present study is the first to validate the CRS
proposed by Bohm et al., but further studies that incorporate additional
biomarkers of response and prognosis are required. In conclusion, the CRS may
predict survival in patients with HGSOC after NACT, but until its prognostic value
has been proven, caution should be exercised before this scoring system is
incorporated into routine practice.
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2.6 Supplementary data tables
Table 8. Supplementary multivariate survival analysis of prognostic factors for
progression free survival for time with chemotherapy as a categorical variable.

Factors

Hazard
ratio

Multivariate analysis
(N= 71)
95% Confidence
Interval

p

CRS Score
Score 1

1.68

0.75 – 3.91

0.225

Score 2

1.04

0.48 – 2.34

0.925

Score 3

1.00

-

-

Age at

1.00

0.28 – 1.21

0.873

diagnosis
Time to chemotherapy (days)
< 28

1.00

 28

0.86

-

-

0.42 – 1.75

0.678

Chemotherapy regimen
q1 weekly

1.00

-

-

q3 weekly

1.00

0.47 – 2.12

0.995

IIIC

1.00

-

-

IV

0.63

0.28 – 1.41

0.266

1.00

-

-

2.17

1.11 – 4.21

0.023

R0

1.00

-

-

Any disease

1.96

0.97 – 3.98

0.061

FIGO stage

Disease distribution
Lower
abdominal
Upper
abdominal
Residual disease at IDS

present
Overall percentage difference in CA-125 score
< 86 %

1.00

-

-

 86 %

0.58

0.28 – 1.21

0.148

CA, Cancer Antigen; CRS, Chemotherapy Response Score; FIGO, International
Federation of Gynecology and Obstetrics; IDS, Interval debulking surgery
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Table 9. Supplementary multivariate survival analysis of prognostic factors.

Multivariate analysis
(N= 71)
Factors

Hazard ratio

95% Confidence
Interval

p

CRS Score
Score 1

1.81

0.45 – 7.28

0.403

Score 2

0.97

0.25 – 3.85

0.968

Score 3

1.00

-

-

Age at diagnosis

1.03

0.97 – 1.09

0.369

< 28

1.00

-

-

 28

1.31

0.38 – 4.54

0.669

q1 weekly

1.00

-

-

q3 weekly

1.68

0.53 – 5.34

0.377

IIIC

1.00

-

-

IV

1.47

0.49 – 4.39

0.493

Lower abdominal

1.00

-

-

Upper abdominal

2.29

0.80 – 6.55

0.124

R0

1.00

-

-

Any disease present

3.58

1.14 – 11.22

0.029

Time to chemotherapy (days)

Chemotherapy regimen

FIGO stage

Disease distribution

Residual disease at IDS

Overall percentage difference in CA-125 score
< 86 %

1.00

-

-

 86 %

0.46

0.16 – 1.33

0.152

CA, Cancer Antigen; CRS, Chemotherapy Response Score; FIGO, International
Federation of Gynecology and Obstetrics; IDS, Interval debulking surgery.
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Table 10. Fischer's exact test investigating if CA-125 reduction clinically
correlated to CRS.
CA-125 (N = 68)
< 86%

 86 %

Total

Score 1

7

11

18

Score 2

6

22

28

Score 3

6

16

22

Total

19

49

81

CRS

** Fisher’s exact test = 0.751

Table 11. Fischer's exact test investigating if a change in chemotherapy regimen
was clinically correlated to CRS and progression free survival.
Progression status
Chemotherapy
changed status

No
progression

Progressed

Total

Yes

1

7

8

No

1

10

11

Total

2

17

19

** Fisher’s exact test = 1.00

Table 12. Fischer's exact test investigating if a change in chemotherapy regimen
was clinically correlated to CRS and overall survival.
Survival status
Chemotherapy
changed status
Yes

Alive

Died

Total

2

6

8

No

6

5

11

Total

8

11

19

** Fisher’s exact test = 0.352
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3.1 Introduction

The main purpose of this thesis was to test the hypothesis that the CRS score
was associated with the survival outcomes in patients with advanced HGSOC
undergoing NACT-IDS. This study successfully met its first objective by externally
validating the three-tier CRS developed by Bohm et al. (15) The three anatomical
pathologists who participated in this study showed ease and reproducibility of
assigning a CRS to our Western Australian study of 71 women.

Similarly, this study also found that outcomes for both PFS and OS were in
keeping with the original paper by Bohm et al. and addressed the second
objective of the thesis, which was to determine the prognostic significance of the
CRS score in advanced ovarian cancer.

Since the publication of the paper there have been three further groups publish
on both the reproducibility of the CRS as well as its prognostic significance for
progression free survival and overall survival. (113-115) Singh et al., in a slightly
larger cohort of 100 Indian patients showed that CRS did not correlate to PFS in
multivariate modelling when adjusting for debulking status with CRS 1+2 having
16 months PFS vs CRS 3 18 months PFS. However, these varying results could
be explained by less than 25% of the patients in their study group being optimally
debulked compared with over 50% in our group and 45% in the original Bohm et
al. paper. Optimal debulking and residual disease post-surgery is considered the
most important factor affecting progression free and overall survival.

The second publication since our paper by Lee et al. involved 110 Korean
women and showed that CRS was significant for PFS in CRS 1+2 compared with
CRS 3 being 14.5 and 18.6 months respectively. (114) However, only one third of
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the patients in this cohort had six total cycles of chemotherapy, compared with
85% of the patients in our study having six total cycles of chemotherapy in
keeping with current recommended international practice.

A third group from the Dana Faber Cancer Centre in Boston have recently
published an analysis of the CRS in 68 patients and consistent with the findings
of the previous studies, found that a CRS of 1 or 2 was associated with a shorter
median progression-free survival (10.9 months; 95% confidence interval, 9-14)
compared to a CRS of 3 (18.9 months; 95% CI, 18-24; P=0.020).

Drawing on these data from Canada and the United Kingdom, Australia, India,
Korea and the United States, these five papers have demonstrated that the CRS
is a reproducible and prognostic tool for women with advanced HGSOC
undergoing NACT-IDS.

3.2 Implications of research findings
The three-tier CRS classification system based on histopathological examination
has been recently proposed for HGSOC to assess response to NACT by the
International Collaboration on Cancer Reporting. (19) Universal adoption of CRS
may have the following implications for clinical practice:


Be utilised as a predictor of PFS and OS for patients that are selected for
NACT and IDS.



Be utilised as an endpoint for clinical trials investigating novel
chemotherapy, immunotherapy and targeted agents. (116)



Act as a biomarker for NACT response in women with advanced disease
and may allow for rapid assessment of drug efficiency in clinical trials.



Provide additional information to support the counselling of patients that
need to determine continuation of chemotherapy or to cease curative

67

treatment and seek palliative care services to ensure quality of life is
maximised in final stages of life.


e implemented into guidelines for ‘best practice’ to manage women
diagnosed with HGOSC who are treated by NACT.

3.3 Strengths and limitations
A major strength of this study is that it was based on all patients diagnosed with
HGSOC from a stable and isolated Western Australia population. The benefits of
this include:


Almost complete case ascertainment;



Minimal loss to follow-up;



Findings are applicable to the wider Australian setting; and



Pathology review conducted by experts in the area.

The study does, however, also have some limitations, which include the selection
bias that is inherent in its retrospective design and the relatively short median
follow-up. As with all retrospective studies, the data utilised has a number of
constraints. Examples may include, the quality of the data (e.g. data
completeness), confounding variables that may not be present in the dataset
(e.g. lifestyle factor or other existing comorbidities), and lack of other relevant
clinical details (i.e. a patient’s choice to cease treatment). Extending the duration
of follow-up time would increase the study’s power to perform multivariate models
controlled for confounders (i.e. stage of disease, residual disease and patient age
of diagnosis).

The first patients that were included into this study and underwent IDS, were prior
to the landmark papers of Vergote et al. (2) and CHORUS. (1) In these earlier
years IDS would have been chosen as the best treatment option for these
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patients as they would have been deemed to not be ideal surgical candidates,
thus there would also be the factors of the patient’s poor functional status and
medical comorbidities.

Germline and somatic BRCA mutation status is also associated with improved
PFS and OS; however, it was not possible to ascertain BRCA status for over 60%
of the cohort in this thesis as referral for mutation testing was not part of routine
care in Western Australia until 2013, and it is possible that this may have biased
the results.

3.4 Future avenues for research
Worldwide the management of women with HGSOC remains challenging due to
the disease being diagnosed at a late stage in the majority of cases. The
following research is now being undertaken to further explore the clinical
significance and role of the CRS for patients diagnosed with HGSOC and are well
suited to NACT with IDS:


An international multicentre patient level meta-analysis that stratifies
patients into CRS categories to further the prognostic validation of PFS
and OS.



Correlating CRS categories with HGSOC molecular subtypes; for
example, one might hypothesise that patients with a CRS3 (complete or
near complete pathological response to NACT) would enrich for germline
or somatic BRCA mutations or other defects in the homologous DNA
repair pathway.



The importance of the CRS and its role in predicting patients with
platinum resistant disease: implications to enhance their management
and molecular modelling/biomarkers to extend/improve survival outcomes
for these patients.
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The CRS may be used as an endpoint in clinical trials as a surrogate for
survival. Indeed, a Western Australian led phase II study, “iPRIME”
(ACTRN1261800010920) will investigate two immunotherapy agents,
Durvalumab and Tremelimumab, in combination with standard NACT in
newly diagnosed women with advanced

GSOC and the trial’s primary

endpoint is the CRS.

The CRS appears to be a surrogate marker for progression-free survival in
women with advanced HGSOC treated by NACT and may also be used as an
endpoint in clinical trials to allow for rapid assessment of therapeutic efficacy.
This may also have the potential to expedite both the development and approval
of differing treatments for patients with early stage disease, which currently
occurs in patients with breast cancer. (117)
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